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Background: The conventional expansion of human mesenchymal stromal cells
(hMSC) for tissue engineering or (pre-) clinical investigation includes the use of 10%
fetal bovine serum (FBS). However, there exists immense lot-to-lot variability in FBS
samples and time consuming as well as cost intensive lot pre-testing is essential to
guarantee optimal hMSC proliferation and stem cells characteristics maintenance.
Furthermore, lot-to-lot variability impedes the long-term consistency of research and
comparability between research groups. Therefore, we investigated the use of
defined, invariable, non-synthetic FBS in low serum culture conditions for isolation
and expansion of hMSC.
Methods: hMSC were isolated from bone marrow in Panserin 401 supplemented
with growth factors and 2% MSC-tested or non-tested, defined, invariable, non-
synthetic FBS and further cultivated in vitro. The surface marker expression,
differentiation capacity as well as cell proliferation and cytotoxicity was analyzed and
compared between serum samples.
Results: Cells isolated and cultivated with low concentrations of MSC-tested or non-
tested FBS demonstrated no differences in surface marker expression or
differentiation capacity. Proliferation of hMSC was equal in medium supplemented
with either serum with no indication of cell death.
Conclusions: The low serum concentration in Panserin 401 supplemented with
growth factors enables the use of defined, invariable, non-synthetic FBS for the
isolation and expansion of hMSC. The required hMSC characteristics like surface
marker expression and differentiation capacity are maintained. Importantly, no
differences in the cell proliferation could be detected. Therefore, using these low-
serum culture conditions, the need for lot-to-lot pre-testing of FBS usually needed
for optimal hMSC expansion is abolished leading to long-term consistency and
comparability of results.
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The therapeutic application of human mesenchymal stromal cells (hMSC) is of great
interest in a variety of diseases including graft-versus-host disease (GvHD) [1,2], osteo-
genesis imperfecta [3,4], acute myocardial infarction [5,6], spinal cord injury [7,8], mul-
tiple sclerosis [9,10], and critical limb ischemia [11,12]. Although hMSC can
differentiate into adipocytes, osteocytes and chondrocytes [13], the beneficial effect in
the above mentioned diseases is a paracrine mechanism [14]. hMSC are capable of
expressing and releasing a variety of different growth factors (basic fibroblast growth
factor (bFGF), epidermal growth factor (EGF), hepatocyte growth factor (HGF),
platelet-derived growth factor (PDGF), stromal-derived growth factor 1α (SDF-1 α),
transforming growth factor β (TGF-β), vascular endothelial growth factor (VEGF)) and
cytokines (interleukin 1 β (IL-1β), IL-6, IL-8, tumor necrosis factor α (TNFα)) in a
donor-dependent manner [15-19].
For tissue engineering purposes as well as for the clinical application of hMSC, ad-
equate numbers of viable, transplantable (autologous or allogenic) cells need to be
generated. Since hMSC represent only a small proportion (0.01-0.02%) of bone marrow
cells, the expansion to high cell numbers is crucial [20]. The conventional applied
medium for such expansion procedures is Dulbecco’s modified Eagle Medium (DMEM)
supplemented with 10% fetal bovine serum (FBS) [21]. FBS has, however, the disadvan-
tage that there exists immense lot-to-lot variability and unexpected cell growth
characteristics [22]. To overcome these difficulties, time-consuming lot pre-testing is
required to guarantee optimal cell growth and maintenance of hMSC characteristics.
Alternatively, the use of commercial hMSC-tested serum can be applied. However,
these pre-tested sera are highly expensive and lot-to-lot variability still exists. In a pre-
vious study, we were able to develop serum-reduced culture conditions for even better
hMSC proliferation than conventional DMEM with 10% FBS [23]. This serum-reduced
medium consists of Panserin 401 supplemented with only 2% FBS and growth factors.
The aim of the current study was to evaluate if this low serum concentration can be
replaced by defined, invariable, non-synthetic FBS which is available at around 10% of
the costs of commercially pre-tested sera and guarantees the consistency and compar-
ability of research results.Methods
Cell culture
Cancellous bone fragments were obtained during operation procedures from four fully
anonymous patients (with informed consent according to local ethical board approval
of the University Hospital, Aachen) and selected by their plastic adherence as
demonstrated previously [15,17,23]. Briefly, bone fragments were washed with Panserin
401 media (Pan Biotech GmbH, Aidenbach, Germany) supplemented with 2% FBS
(hMSC-tested serum: PromoCell, Heidelberg, Germany; non-tested serum: FBS Gold,
PAA Laboratories GmbH, Pasching, Austria) and growth factors (10 ng/ml EGF, 1 ng/
ml bFGF, 1 ng/ml PDGF-BB; all PeproTech GmbH, Hamburg, Germany) and 10 nM
dexamathasone (Sigma, Steinheim, Germany). The collected media was centrifuged
with 500 g for 5 min and the cell pellet was resuspended in 10 ml fresh media, trans-
ferred to a T75 flask (Greiner Bio-One, Frickenhausen, Germany) and maintained in a
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removed by media exchange on the next day. Medium exchange was performed every
3–4 days. Pictures were taken using a Leica DMI4000 B microscope (Leica, Wetzlar,
Germany) and Diskus software (Carl H. Hilgers Technisches Büro, Königswinter,
Germany). When the cells reached nearly confluence, they were detached with trypsin/
ethylene diamine tetra acetic acid (EDTA) (PAA) and re-seeded with a density of
4000 cells/cm2. All experiments were performed with cells of passage 1.hMSC characterization
Surface marker profiles and multipotent differentiation capacities of isolated hMSC of
those four donors were analyzed according to the guidelines set by the Mesenchymal
and Tissue Stem Cell Committee of the International Society for Cellular Therapy [13]
as demonstrated previously [23,24].
To detect specific surface antigens, cells were detached and fixed with 4%
paraformaldehyde for 20 min. After washing with 0.1 M phosphate-buffered saline
(PBS), cells were incubated in blocking solution (20% FBS in PBS) for 20 min. After
washing with PBS, the cell pellets (300,000 per antibody) were resuspended in 100 μl
PBS, 2 μl primary antibody was added and incubated for 30 min. Monoclonal primary
antibodies recognizing surface markers CD11b (Invitrogen, Carlsbad, USA), CD19,
CD34, CD45, CD73, CD90 (Becton Dickinson, San Jose, USA), CD105 (Invitrogen)
and HLA-DR (Abcam, Cambridge, UK) were used. After three washing steps with
PBS, 2 μl of the secondary antibody (Alexa-488 conjugated goat anti-mouse,
Invitrogen) was incubated in 100 μl PBS for 30 min in the dark. After two final
washing steps, the cells were re-suspended in 400 μl PBS and analyzed using a
FACSCalibur and FACSCalibur software (Becton Dickinson, Heidelberg, Germany).
For adipogenic differentiation, hMSC were cultivated alternately in adipogenic in-
duction medium and adipogenic maintenance medium for 3–4 days for 3 weeks.
Adipogenic induction medium consisted of DMEM (Lonza, Verviers, Belgium)
containing 10% FBS, 0.01 mg/ml insulin, 0.2 μM indomethacin, and 0.5 mM isobutyl-
methyl-xanthine (all Sigma). Adipogenic maintanance medium consisted of DMEM
supplemented with 10% FBS and 0.01 mg/ml insulin. Oil Red O staining (Sigma) was
used to visualize lipid droplets formation in differentiated adipocytes. Osteogenic dif-
ferentiation was induced by cultivation of hMSC in DMEM containing 10% FCS,
10 nM sodium β-glycerophosphate, 100 nM dexamethasone, and 0.05 mM 1-ascorbic
acid 2-phosphate (all Sigma). Medium was changed every 3 days for 3 weeks. Osteogenic
differentiation was visualized by Alizarin Red S (Sigma) staining to demonstrate
matrix mineralization associated with osteoblast differentiation.Proliferation and cytotoxicity
Cell proliferation and cytotoxicity were measured using the CellTiter-Blue Cell Viability
Assay and CytoTox-ONE Homogeneous Membrane Integrity Assay (Promega, Madison,
USA) according to the manufacturer’s protocol twice a week for two weeks without passa-
ging of cells [23]. Therefore, 5 × 104 cells of four donors were seeded into 12-wells and
grown in culture media supplemented with the different sera. For cytotoxicity measure-
ment, 100 μl of the supernatant were transferred into a black 96-well plate, and incubated
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was diluted 1:5 in medium and 1 ml added to each well for 1 h at 37°C and 5% CO2.
Subsequently, 200 μl of the supernatant were transferred into a black 96-well plate. For
both assays fluorescence intensity was measured using the fluorometer FLUOstar
OPTIMA (BMG Labtech, Jena, Germany) with an excitation at 560 nm and emission at
590 nm. After washing with medium, 1 ml fresh medium was added to the cells and
incubated until the following measurement.Statistical analysis
All data are presented as the mean value ± SD. Statistical differences were determined
by one-way ANOVA followed by Bonferroni post hoc testing. A p value of less than
0.05 was considered to be significant. All the statistical analyses and the evaluation of
data were performed using GraphPad Prism version 4.03 (GraphPad Software, San
Diego, USA).Results
To evaluate if serum-reduced culture conditions for expansion of bone marrow-derived
hMSC to relevant cell numbers for tissue engineering purposes or direct clinical ap-
plication might be performed with defined, invariable, non-synthetic FBS rather
than MSC-tested FBS, hMSC of four different donors were isolated in Panserin 401
supplemented with growth factors and 2% MSC- or non-tested serum. Cultivated
hMSC were characterized according to the Mesenchymal Stem Cell Committee of the
International Society for Cellular Therapy [13] by three criteria: (I) adherence to tissue
culture plastic, (II) specific surface marker expression, and (III) multipotent differenti-
ation capacity.
Isolation of hMSC was performed simultaneously in Panserin 401 medium
supplemented with 2% MSC-tested or non-tested serum (Figure 1A + B). Cell growth
was monitored after 7 (Figure 1C + D) and 14 days (Figure 1E + F). After 14 days in
culture, hMSC grown with either serum demonstrated confluent cultures which were
further processed for surface marker and differentiation capacity analysis.
Fluorescent activated cell sorting (FACS) analysis of adherent hMSC isolated and
expanded with both sera demonstrated the expression of the surface markers CD73,
CD90 and CD105, as well as the absence of CD11b, CD19, CD34, CD45 and HLA-DR
(Figure 2). To investigate the multipotent differentiation potential of hMSC isolated
and cultivated with both sera, hMSC were differentiated into adipocytes and osteocytes.
Alizarin Red S staining was performed to detect mineral deposition after osteogenic dif-
ferentiation (Figure 3A + B). No staining differences between the different sera could
be identified. Oil Red O staining was applied to visualize the lipid vacuoles in
differentiated adipocytes (Figure 3C + D). No differences in the degree of lipid vacuole
production could be detected between the employed sera.
Besides the maintenance of hMSC characteristics by applied culture conditions, the
growth promoting properties of the individual serum is of great importance. Therefore,
hMSC isolated and grown in both sera were evaluated regarding their proliferative cap-
acity. The day after seeding 5 × 104 cells into each well, the measurement of day 1
revealed that hMSC that were cultivated in non-tested serum demonstrated lower cell
Figure 1 Isolation of hMSC with MSC-tested or non-tested serum resulted in similar cell
morphology and cell growth. Cell growth of isolated hMSC was monitored after d4 (A + B), d7 (C + D)
and d14 (E + F). Growth of hMSC in either serum resulted in confluent cultures after 14d. Scale: 200 μm.
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this difference was not significant (MSC-tested serum: 4.6 ± 0.6 × 104 cells; non-tested
serum: 2.6 ± 0.9 × 104 cells). Cells of all four donors proliferated in both sera and hMSC
grown with non-tested serum reached equal cell numbers after 7 days in culture (MSC-
tested serum: 9.5 ± 1.3 × 104 cells; non-tested serum: 9.0 ± 2.6 × 104 cells). At the end of
the experiment at 14 days after seeding, hMSC grown in both sera demonstrated con-
fluent cell cultures (MSC-tested serum: 13.3 ± 1.1 × 104 cells; non-tested serum: 12.6 ±
1.8 × 104 cells). Furthermore, evaluation of the cytotoxicity was performed to detect cell
death. Neither of the applied sera demonstrated any cytotoxicity to cultivated hMSC
over the whole experimental procedure.Discussion
The use of pre-tested sera is essential to guarantee optimal hMSC proliferation and
maintenance of hMSC characteristics. The aim of the current study was to investigate
if in low serum culture conditions MSC-tested serum might be exchanged by defined,
invariable, non-synthetic FBS. Therefore, hMSC of four different donors were isolated
Figure 2 No alteration of hMSC surface marker expression after isolation and cultivation with MSC-
tested or non-tested serum. FACS analysis of the immunophenotypic surface profile for CD11b, CD19,
CD34, CD45, CD73, CD90, CD105 and HLA-DR show no differences between hMSC isolated and expanded
with MSC-tested or non-tested FBS. Red histograms represent the fluorescence from negative control cells
incubated with only secondary antibody.
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differentiation capacity and cell proliferation. Analysis of the surface marker expres-
sion demonstrated the existence of CD73, CD90 and CD105 as well as the absence of
CD11b, CD19, CD34, CD45 and HLA-DR of hMSC expanded with either serum.
Furthermore, the differentiation capacity into adipocytes and osteocytes was not
affected by the different sera. According to the Mesenchymal Stem Cell Committee of
the International Society for Cellular Therapy [13], all cells isolated by media
supplemented with MSC-tested or non-tested serum were proved to be hMSC.
Important for tissue engineering purposes as well as for the clinical application of
isolated hMSC is, however, the generation of relevant cell numbers. In a previous study,
we were able to demonstrate higher cell proliferation using low serum culture
conditions based on Panserin 401 than the conventional applied DMEM with 10% FBS
[23]. Comparison of the hMSC proliferation in Panserin 401 supplemented with growth
factors and 2% of MSC-tested or non-tested serum revealed no significant differences.
Figure 3 Differentiation capacity of hMSC is not altered by cultivation with MSC-tested or non-
tested serum. hMSC isolated and cultivated with MSC-tested or non-tested FBS were differentiated using
osteogenic or adipogenic induction protocols for three weeks. Osteogenic differentiation (A + B) was
demonstrated by Alician Red S staining of mineral depositions and adipogenic differentiation (C + D) by Oil
Red O staining of lipid droplets. Scale: 100 μm.
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with non-tested serum. However, this difference was not significant and could be
explained by discrepancies in attachment factor concentration which might also exist
between different MSC-tested lots. Since hMSC cultivated with non-tested serum
reached equal cell numbers already after 7 days in culture, this lower attachment cap-
acity can be disregarded. In conclusion, hMSC isolated and cultivated in Panserin 401
supplemented with growth factors and 2% non-tested FBS maintain their cell-specific
characteristics and proliferative capacity.Figure 4 Cell proliferation of hMSC is not altered by cultivation with MSC-tested or non-tested
serum. Cell Proliferation and cytotoxicity was monitored every 3–4 days using CellTiter-Blue Cell Viability
Assay and CytoTox-ONE Homogeneous Membrane Integrity Assay. No significant differences in cell
proliferation could be observed between hMSC isolated and cultivated in MSC-tested or non-tested FBS
(black graph). None of the applied sera induced cell death (grey graph). Data are expressed as mean
values ± SD.
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purified and fractionated. Afterwards, the individual constituents are recombined to
guarantee the defined composition (www.paa.com). The advantage of the use of this
FBS is, besides the lower price, that the necessity of serum lot testing is abolished.
Furthermore, research groups from all over the world could work with the same FBS
which might lead to more comparable results as well as an efficient transfer of results
to the clinic.
In an attempt to eliminate FBS in hMSC culture conditions, Lohmann et al. [25]
investigated the use of human platelet lysate (HPL). Primary isolation and differenti-
ation by using 10% HPL could be achieved; however, the HPL donor age immensely
affected hMSC proliferation rate.
Other groups (see Table 1) attempt to totally eliminate FBS or human serum
components in hMSC cultivation since serum always carries the risk for the transmis-
sion of infectious agents and the potential for promoting or enhancing immune rejec-
tion [26,27]. The approach by Mimura et al. is based on a medium that was initially
developed for embryonic stem cell cultivation [25] and further supplemented with
bFGF, heparin and TGF-β1 [26]. In their investigation, they cultivated an hMSC cell
line (UE7T-13) and demonstrated the maintenance of CD73, CD90 and CD105 expres-
sion as well as adipogenic and osteogenic differentiation capacity. However, these
results were obtained with a single hMSC cell line and the capacity to efficiently isolate
hMSC from bone marrow using this serum-free culture medium still needs to be
demonstrated. Chase and colleagues employed a commercially available medium
(StemPro MSC SFM by Invitrogen) to investigate hMSC proliferation [27]. Although
this serum-free medium revealed the same proliferation rate than the conventional
DMEM with 10% FBS, the differentiation capacity was only presented in samples that
were isolated with serum-containing medium. Furthermore, the manufacturer himself
only demonstrated the tri-lineage differentiation capacity of hMSC grown in this spe-
cial serum-free culture medium (www.invitrogen.com). The differentiation capacity of
cells that were isolated in this medium is still lacking. Although these chemically-
defined media are thought to be safer and therefore better for clinical settings, the pro-
priety composition of these hMSC culture media might impede the clinical acceptance.
Even though the use of FBS in hMSC culture media is of concern, hMSC isolated and
cultivated in FBS-containing medium have been approved by the US Food and Drug
Administration (FDA) for use in a variety of clinical trials (http://clinicaltrials.gov).Table 1 Main cultivation protocols of human bone marrow-derived MSC (grey: serum-
free protocol)
Medium Reference Primary isolation
demonstrated
Differentiation
demonstrated
DMEM 10% FBS Chase et al. [27], Lohmann
et al. [28], Montzka et al. [23]
yes yes
DMEM/F12 20% FBS or 20% human
autologous serum or 20% human
allogenic serum
Shahdadfar et al. [21] yes yes
DMEM 10% HPLs Lohmann et al. [28] yes yes
Panserin 401 2% FBS and GF Montzka et al. [23] yes yes
ESF basal medium and supplements Mimura et. al [26] no yes
Stem Pro MSC SFM (Invitrogen) Chase et al. [27] no yes
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In conclusion, the current study demonstrated the isolation, expansion and mainten-
ance of hMSC characteristics by the use of low serum concentrations using a defined,
invariable, non-synthetic FBS. This media composition enables the generation of con-
sistent research results over long periods and importantly, simplifies the collaboration
and comparability within different research groups.
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